October 2023

A statement to the ASX on Monday revealed major changes to the board, including a new chairperson and two board nominees for the annual general meeting (AGM) on November 9. All of this appears to be endorsed by the top shareholder, Solomon Lew, and his Premier Investments group. Myer (ASX:MYR) announced that after seven years, […]

Newmont’s $A29 billion all-paper takeover of Newcrest (ASX:NCM) has proven to be a far more significant deal than initially anticipated. This acquisition not only adds over 2 million ounces of gold output annually and more than 140,000 tonnes of copper, along with silver and molybdenum, to Newmont’s already leading global position but also strengthens its

Stocks staged a comeback Monday as investors shook off pressures driven by the deadly Israel-Hamas conflict. The Dow Jones Industrial Average was higher by 0.6 per cent, or 185 points. The S&P 500 was also higher by 0.6 per cent, meanwhile, and the tech-heavy Nasdaq Composite added 0.4 per cent. The major indexes were down

On Monday, the ASX experienced gains, primarily driven by a significant increase in energy and gold stocks. This surge was a result of a sharp rise in oil prices in Asia, triggered by recent violent incidents involving Hamas in Israel. The benchmark S&P/ASX 200 index increased by 0.2 percent, adding 16 points to reach 6970.2

The S&P/ASX 200 is trading 0.51 per cent higher at 6,989.40. Futures The SPI futures are up 39 points. Best and worst performers The best-performing sector is Energy, up 3.23 per cent. The worst-performing sector is Consumer Staples, down 0.63 per cent. The best-performing large cap is Evolution Mining (ASX:EVN), trading 7.34 per cent higher

The ASX experienced a rise in its benchmark index, the S&P/ASX 200, by 0.5%, gaining 34 points to reach 6988.2 at midday. This increase was primarily driven by a rally in energy and mining stocks, which was a response to the surge in oil prices in Asia. The oil price surge was triggered by recent

Radiopharm Theranostics (ASX:RAD) announced it has been granted Human Research Ethics Committee approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1- positive non-small cell lung cancer. The trial is expected to start shortly. Shares are trading flat at 13 cents. Talon Energy (ASX:TPD) announced an update